RNAs were isolated from the murine (BR-5, BR-Luc) and human (IGROV1, SKOV3, A2780 E-80, and A2780) EOC cell lines using
TRIzol reagent (Life Technologies). cDNAs were synthesized with random hexamers and MuLV reverse transcriptase (including
RNase inhibitor; Applied Biosystems), and purified using a
QIAquick PCR Purification Kit (Qiagen).
Human cDNAs were purchased from Origene (HORT502) containing 48 lyophilized cDNAs from EOC patient specimens (8 stage I, 9 stage II, 17 stage III, and 6 stage IV) and 8 cDNAs from normal ovaries. Patient pathology characteristics are in Supplemental Table
S1.
Quantitative real-time RT-PCR was performed using a Roche
LightCycler 480 real-time PCR (Roche Diagnostics) with gene-specific primers for mouse PCFT, RFC, GARFTase, AICARFTase, and FRα, or human GARFTase and AICARFTase, as appropriate (Supplemental Table
S2), and
FastStart DNA Master SYBR Green I Reaction Mix (Roche Diagnostics, Indianapolis, IN). Transcript levels were normalized to β-actin transcripts. For the murine transcripts, levels were normalized to transcript levels in mouse liver.
Wallace-Povirk A., Rubinsak L., Malysa A., Dzinic S.H., Ravindra M., Schneider M., Glassbrook J., O’Connor C., Hou Z., Kim S., Back J., Polin L., Morris R.T., Gangjee A., Gibson H, & Matherly L.H. (2022). Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment. Scientific Reports, 12, 11346.